JP2016508143A - ヒト血清アルブミン結合化合物およびその融合タンパク質 - Google Patents

ヒト血清アルブミン結合化合物およびその融合タンパク質 Download PDF

Info

Publication number
JP2016508143A
JP2016508143A JP2015551157A JP2015551157A JP2016508143A JP 2016508143 A JP2016508143 A JP 2016508143A JP 2015551157 A JP2015551157 A JP 2015551157A JP 2015551157 A JP2015551157 A JP 2015551157A JP 2016508143 A JP2016508143 A JP 2016508143A
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
acid sequence
seq
serum albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015551157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508143A5 (OSRAM
Inventor
ブラー ファビアン
ブラー ファビアン
ビュルナー ウルリッヒ
ビュルナー ウルリッヒ
ツビンデン イレーネ
ツビンデン イレーネ
アッティンガー−トラー イザベッラ
アッティンガー−トラー イザベッラ
フォン デア ベイ ウルリーケ
フォン デア ベイ ウルリーケ
ケーニッヒ−フリードリヒ スーザン
ケーニッヒ−フリードリヒ スーザン
ベルトシンガー ジュリアン
ベルトシンガー ジュリアン
グラウブロウスキ ドラガン
グラウブロウスキ ドラガン
ヘンネ パトリシア
ヘンネ パトリシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Covagen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen AG filed Critical Covagen AG
Publication of JP2016508143A publication Critical patent/JP2016508143A/ja
Publication of JP2016508143A5 publication Critical patent/JP2016508143A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015551157A 2013-01-03 2013-12-18 ヒト血清アルブミン結合化合物およびその融合タンパク質 Pending JP2016508143A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13150171.0 2013-01-03
EP13150171.0A EP2752426A1 (en) 2013-01-03 2013-01-03 Human serum albumin binding compounds and fusion proteins thereof
PCT/EP2013/077227 WO2014106583A1 (en) 2013-01-03 2013-12-18 Human serum albumin binding compounds and fusion proteins thereof

Publications (2)

Publication Number Publication Date
JP2016508143A true JP2016508143A (ja) 2016-03-17
JP2016508143A5 JP2016508143A5 (OSRAM) 2017-01-12

Family

ID=47458817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015551157A Pending JP2016508143A (ja) 2013-01-03 2013-12-18 ヒト血清アルブミン結合化合物およびその融合タンパク質

Country Status (7)

Country Link
US (2) US9790475B2 (OSRAM)
EP (2) EP2752426A1 (OSRAM)
JP (1) JP2016508143A (OSRAM)
AU (1) AU2013372004B2 (OSRAM)
CA (1) CA2896962A1 (OSRAM)
HK (1) HK1215441A1 (OSRAM)
WO (1) WO2014106583A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517307A (ja) * 2020-03-06 2023-04-25 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 血清アルブミン結合ナノボディ組成物、及びその使用方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016534984A (ja) 2013-10-01 2016-11-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ アフィニティークロマトグラフィーのためおよび治療薬の半減期の延長のための化合物
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018220516B2 (en) 2017-02-16 2025-03-06 Sonnet BioTherapeutics, Inc. Albumin binding domain fusion proteins
CN107353346A (zh) * 2017-08-09 2017-11-17 芜湖英特菲尔生物制品产业研究院有限公司 一种由猪白蛋白与猪干扰素γ组成的融合蛋白及其制备方法和一种重组猪长效干扰素γ
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
CN116284373A (zh) * 2020-08-14 2023-06-23 上海洛启生物医药技术有限公司 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500875A (ja) * 2006-08-21 2010-01-14 アイトゲネシシェ・テヒニーシェ・ホッホシューレ・チューリッヒ Ｆｙｎキナーゼの改変ｓｈ３ドメインを含む特異的かつ高親和性の結合タンパク質

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof
MX354717B (es) * 2012-03-16 2018-03-16 Covagen Ag Moleculas de union novedosas con actividad antitumoral.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500875A (ja) * 2006-08-21 2010-01-14 アイトゲネシシェ・テヒニーシェ・ホッホシューレ・チューリッヒ Ｆｙｎキナーゼの改変ｓｈ３ドメインを含む特異的かつ高親和性の結合タンパク質

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROTEIN ENGINEERING, DESIGN ＆ SELECTION, vol. 20, no. 2, JPN6017044410, 2007, pages 57 - 68, ISSN: 0003845726 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517307A (ja) * 2020-03-06 2023-04-25 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 血清アルブミン結合ナノボディ組成物、及びその使用方法
JP7754510B2 (ja) 2020-03-06 2025-10-15 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 血清アルブミン結合ナノボディ組成物、及びその使用方法

Also Published As

Publication number Publication date
AU2013372004A1 (en) 2015-07-16
HK1215441A1 (zh) 2016-08-26
US20190169581A1 (en) 2019-06-06
EP2941439B1 (en) 2018-01-31
CA2896962A1 (en) 2014-07-10
US20160076011A1 (en) 2016-03-17
WO2014106583A1 (en) 2014-07-10
EP2941439A1 (en) 2015-11-11
EP2752426A1 (en) 2014-07-09
US9790475B2 (en) 2017-10-17
US10364419B2 (en) 2019-07-30
AU2013372004B2 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
US10364419B2 (en) Human serum albumin binding compounds and fusion proteins thereof
US20210198380A1 (en) Anti-cancer fusion polypeptide
AU2018220516B2 (en) Albumin binding domain fusion proteins
KR20220113491A (ko) 재조합 펩티드-mhc 복합체 결합 단백질 및 이의 생성 및 용도
JP2021524268A (ja) Ｐｄ−ｌ１及びｃｄ１３７に結合する抗体分子
JP2020515256A (ja) 改良された抗原結合受容体
US12331090B2 (en) Multispecific proteins
KR20140135251A (ko) 항종양 활성이 있는 신규 결합 분자
KR20220079847A (ko) 키메라 직교성 수용체 단백질 및 사용 방법
JP2021533203A (ja) Ｃｄ１３７とｐｄ−ｌ１に特異的な新規融合タンパク質
KR20230042292A (ko) 개선된 항원 결합 수용체
CN119143873A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
US20240279343A1 (en) Multi-specific antibodies and methods of use
JP6840907B2 (ja) ＦＧＦＲ３結合分子ｌｋｏｋｏｋ
KR102846963B1 (ko) IL27Rα 결합 분자 및 사용 방법
JP2025532652A (ja) Ｃｄ１３７およびｃｄ２２８に特異的な新規融合タンパク質
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
TW202502807A (zh) 融合il10多肽
CN121127259A (zh) 用于结合功能障碍的p2x7受体的嵌合抗原受体
HK1249526B (en) Anti-cancer fusion polypeptide
EA042136B1 (ru) Fgfr3-связывающие молекулы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180731